MALARIA
DNDi and its partners are working to ensure access of ASAQ and ASMQ, two antimalarial fixed-dose combination therapies launched in 2007 and 2008. More
ADVOCACY
DNDi and the George Institute launched a new report on the challenges of registering new drugs for neglected diseases in the African context. There is a need to think about new mechanisms and pathways to ensure the urgent approval of new drugs! More
SLEEPING SICKNESS
Developed by DNDi and its partners, NECT, the first new treatment in 25 years against HAT or sleeping sickness, is now available. NECT cuts the cost of treatment, is more convenient for the patients, and significantly reduces the burden on health workers. More
VISCERAL LEISHMANIASIS
At the World Congress on Leishmaniasis held on Feb. 3-7 in India, DNDi organized two symposia on ongoing clinical studies and on early-stage R&D; pipeline. More than 700 attendees from around the world gathered in this event. More
CHAGAS
The first Chagas treatment for children, pediatric benznidazole, will be made available by 2011 by DNDi and Pharmaceutical Laboratory of Pernambuco (LAFEPE) of Brazil More
PORTFOLIO
Current portfolio:Working in partnership with industry and academia, DNDi has built the largest ever R&D; portfolio for the kinetoplastid diseases.
New disease areas:
DNDi has decided to take on two new mini-portfolios: paediatric HIV and helminth infections.
PUBLICATIONS
R&D; for helminth infections
"Potential Drug Development Candidates for Human Soil-Transmitted Helminthiases" by Olliaro P et al. PLoS NTD. 2011 June
Sept 12-16, 2011
31st ISCTRC
Bamako, Mali
DNDi will attend this biennal general conference of the Internation Scientific Council for Typanosomiasis Research and Control
Oct 3-6, 2011
7th European Congress of Tropical Medicine and Hygiene
Barcelona, Spain
As a sponsor, DNDi will have a strong participation with 1 symposium on kinetoplatids and 1 on VL-HIV coinfection, and many oral presentations and posters
Oct 23-26, 2011
World Health Summit
Berlin, Germany
DNDi will co-organize a session on Product Development for Neglected Patients and will take part to the Innovation session
Past
July 17-20, 2011
6th IAS conference
Rome, Italy
With the expansion of its portfolio to paediatric HIV, DNDi attended the IAS conference to advocate on R&D; needs for better adapted drugs for infants
July 8-10, 2011
ISID-NTD meeting
Boston, USA
DNDi attended the firsts NTD meeting of ISID in the following sessions: "Developing the Tools Needed to Fight NTDs" and "Essential Elements: Drug Donations and Nongovernmental Development Programs"
DNDI NEWS
Except where otherwise noted, content on this site is licensed under
a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License